Oncolytics Biotech Inc T.ONC

Deal or no deal!

[Lesalpes29]

We can continue to hope for!

Eli Lilly surged to an all-time high this year and notched a gain of nearly 50 per cent on its suite of products to treat obesity. But today the company is announcing a $1.4-billion deal for a cancer-drug maker. Eli Lilly is buying Point Biopharma, which has a promising drug for prostate cancer that doesn’t respond to hormonal treatment. Shares of Point are rallying as the $12.50 per share offer deal is an 87 per cent premium to yesterday’s closing price. However, it is barely above the $10 per share IPO price from 2020.

[Noteable]

POINT is a radiopharmaceutical company not a cancer-drug company. https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html

[Noteable]

Definitely shows that ONCY is undervalued when an experimental radiopharmaceutical in prostate cancer traded for US$12 per share.

[13X2413]

Investors seem to think its overvalued, judging by the constant pressure on the price. 

[Noteable]

With Point Biopharma, a Phase 3 experimental radiopharmaceutical company in metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment, acquired by Eli Lilly for US$1.4 Billion ... ONCY would be valued at between US$7.5 Billion to US$10 Billion, as previously outlined.

[fox7mf]

87% premium? An 87% buyout premium would get Oncy $3.77 usd a share. This inept crew might be able to pull that off, but a $10b buyout is many months away.

[Capitalista]

I think a buyout at ANY price is many months away.  ONCY is just not behaving like a company seeking a buyout.  They are behaving much more like a company raising money to get through the next year or so.   1.  They just did a $15 million private placement at a price much lower than the closing price at that time. This, predictably, tanked our SP.  There was no